Friday, September 29, 2023


Biotechnology News Magazine

Foresite Capital Raises $173 Million to Fund Foresite Labs Incubated Life Science Companies

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

Foresite Capital, a multi-stage healthcare and life sciences investment firm, today announced it has raised a $173 million fund to further invest in companies launched by Foresite Labs.

Foresite Labs companies will also continue to be supported from Foresite Capital Fund V and its associated opportunities fund. The fund comes on the heels of several major milestones for Foresite Capital including the announcement of its $969 million Fund V and investments in Foresite Labs incubated companies Interline Therapeutics, Alumis and TenSixteen Bio.

Foresite Labs was created in October 2019 to found, build and scale life sciences companies at the intersection of healthcare and data science. One of Foresite Capital’s core beliefs is that by combining machine learning, big data and genomics, life sciences companies can accelerate commercialization from decades to years. Foresite Labs was founded to provide expanded capabilities in company creation.

“Technological breakthroughs in genomics and data science are creating opportunities to drive significant transformation of the healthcare industry,” explained Dr. Vikram Bajaj, CEO of Foresite Labs. “We believe the companies we’re creating can help solve many of the problems the industry faces, and this additional capital will help us do that.”

The Foresite Labs team is led by Foresite Capital managing director, Dr. Vik Bajaj, who is the former chief scientific officer of GRAIL and was the co-founder and chief scientific officer of Verily (formerly Google Life Sciences). The firm utilizes its data science platform to launch and support next-generation therapeutics and healthcare services companies to ultimately improve patient outcomes. Foresite Labs has announced the launch of five companies, and is incubating several additional concepts.

“This fund represents strong affirmation of the potential of the companies being built within Foresite Labs,” explained Jim Tananbaum, founder and CEO of Foresite Capital. “Recently launched companies like Interline Therapeutics, Alumis, Sestina Bio and TenSixteen Bio have the potential to deliver life-saving healthcare solutions in just a few short years through the power of the Foresite Labs platform.”

The $173 million fund was oversubscribed from its initial $150 million target.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine